Article
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Feb 2021
Magbanua M J M, Swigart L B, Wu H-T, Hirst G L, Yau C, Wolf D M, Tin A, Salari R, Shchegrova S, Pawar H, Delson A L, DeMichele A, Liu M C, Chien A J, Tripathy D, Asare S, Lin C-H J, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman L J, van 't Veer L J
Abstract excerpt
BACKGROUND: Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated with favorable outcome. We examined the utility of serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk of metastatic recurrence. PATIENTS AND METHODS: Cell-free DNA (cfDNA) was isolated from 291 plasma samples of 84 high-risk early breast cancer patients treated in the neoadjuvant I-SPY 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.